134 related articles for article (PubMed ID: 32768003)
1. The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors.
Halama N; Haberkorn U
Semin Nucl Med; 2020 Sep; 50(5):389-398. PubMed ID: 32768003
[TBL] [Abstract][Full Text] [Related]
2. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
3. Advances in the therapy of BRAF
Jin Z; Sinicrope FA
Expert Rev Anticancer Ther; 2019 Sep; 19(9):823-829. PubMed ID: 31455117
[No Abstract] [Full Text] [Related]
4. Current status of immunotherapy in gastrointestinal malignancies.
Lorenzen S; Lordick F; Loosen SH; Tacke F; Trautwein C; Roderburg C; Ettrich TJ; Perkhofer L; Reinacher-Schick A; Stein A
Z Gastroenterol; 2020 Jun; 58(6):542-555. PubMed ID: 32018315
[TBL] [Abstract][Full Text] [Related]
5. Endocrine tumors of the gastrointestinal tract.
Haller DG
Curr Opin Oncol; 1994 Jan; 6(1):72-6. PubMed ID: 8204694
[TBL] [Abstract][Full Text] [Related]
6. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
7. T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology.
Amedei A; Niccolai E; D'Elios MM
Clin Dev Immunol; 2011; 2011():320571. PubMed ID: 22110523
[TBL] [Abstract][Full Text] [Related]
8. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for immune therapy in gastrointestinal cancers.
Weinberg BA; Hameed R; Marshall JL
Clin Adv Hematol Oncol; 2019 Feb; 17(2):109-119. PubMed ID: 30845114
[TBL] [Abstract][Full Text] [Related]
10. Promising New Agents for Colorectal Cancer.
Das S; Ciombor KK; Haraldsdottir S; Goldberg RM
Curr Treat Options Oncol; 2018 May; 19(6):29. PubMed ID: 29752549
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.
Amaki-Takao M; Yamaguchi T; Natsume S; Iijima T; Wakaume R; Takahashi K; Matsumoto H; Miyaki M
Oncology; 2016; 91(3):162-70. PubMed ID: 27404270
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.
Li WQ; Kawakami K; Ruszkiewicz A; Bennett G; Moore J; Iacopetta B
Mol Cancer; 2006 Jan; 5():2. PubMed ID: 16403224
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms.
Gonzalez RS
Surg Pathol Clin; 2020 Sep; 13(3):377-397. PubMed ID: 32773190
[TBL] [Abstract][Full Text] [Related]
15. Advances in the diagnosis and treatment of gastrointestinal neuroendocrine tumors.
Lee JE; Evans DB
Cancer Treat Res; 1997; 90():227-38. PubMed ID: 9367086
[No Abstract] [Full Text] [Related]
16. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
17. The Interaction of Genomics, Molecular Imaging, and Therapy in Gastrointestinal Tumors.
Wahl RL
Semin Nucl Med; 2020 Sep; 50(5):471-483. PubMed ID: 32768010
[TBL] [Abstract][Full Text] [Related]
18. Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastrointestinal stromal tumors.
Patil DT; Ma S; Konishi M; Carver PD; Pukay M; Beadling C; Corless CL; Rubin BP
Am J Clin Pathol; 2015 Nov; 144(5):782-9. PubMed ID: 26486743
[TBL] [Abstract][Full Text] [Related]
19. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
20. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.
Demetri GD; Benjamin R; Blanke CD; Choi H; Corless C; DeMatteo RP; Eisenberg BL; Fletcher CD; Maki RG; Rubin BP; Van den Abbeele AD; von Mehren M;
J Natl Compr Canc Netw; 2004 May; 2 Suppl 1():S-1-26; quiz 27-30. PubMed ID: 23573667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
